---
document_datetime: 2023-09-21 19:21:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_en.pdf
document_name: prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.771904
conversion_datetime: 2025-12-23 04:27:10.569993
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | (Invented) name                                                                                                   | Strength   | Pharmaceutical                | Route of                         | Packaging                             | Content (concentration)   | Package size           |
|-----------------|-------------------------------------------------------------------------------------------------------------------|------------|-------------------------------|----------------------------------|---------------------------------------|---------------------------|------------------------|
| EU/1/10/657/001 | Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics | -- 1       | Form Suspension for injection | Administration Intramuscular use | pre-filled syringe (glass) authorised | 0.5 ml                    | 1 pre-filled syringe   |
| EU/1/10/657/002 | Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics | -- 1       | Suspension for injection      | Intramuscular use                | pre-filled syringe (glass)            | 0.5 ml                    | 10 pre-filled syringes |

\\_ \\_1

Influenza virus surface antigens*, inactivated: A/Vietnam/1194/2004 (H5N1) - like strain used (NIBRG-14) 7.5 micrograms** per 0.5 ml dose

* propagated in eggs

** expressed in microgram haemagglutinin.

Adjuvant MF59C.1 containing:

squalene                  9.75 milligrams

polysorbate 80         1.175 milligrams

sorbitan trioleate     1.175 milligrams

<!-- image -->

Medicinal product no longer authorised